Everolimus Modulation of Anti-tumor T CD4 Immune Responses

NCT02837757 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
14
Enrollment
OTHER
Sponsor class

Stopped difficulty of patient recruitment

Conditions

Interventions

Sponsor

Centre Hospitalier Universitaire de Besancon